

Published bi-monthly by:



Multimed Inc.
66 Martin Street
Milton, ON L9T 2R2
Canada

Phone: 905-875-2456
Fax: 905-875-2864
www.multi-med.com

CEO, Founder of Current Oncology:
Lorne Cooper

Current Oncology is indexed/covered in MEDLINE, PubMed, EMBASE, SCOPUS, CrossRef, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, EBSCOhost.com Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC).

Peer Review Policy: All manuscripts are initially reviewed by the editorial staff, and if appropriate, will be assigned to a section editor. If the paper is judged to be suitable for possible publication, it will be sent to two or more external reviewers using our database of experts. All articles undergo this process with the following exceptions, which do not undergo our standard review process:

- Letters to the Editor, Commentaries and Editorials are based on the decision of the Editor, who may ask experts on the merit of their contents.
- Practices Guidelines/Consensus Statements - Special considerations may be made in this case as they are typically authored by experts in the field. The authors of the manuscript are asked to sign a form stating they have approved the manuscript and it is acceptable for publication. If they choose not to sign this, they must provide a list of five potential reviewers to review the manuscript, and the article will go through our standard peer review process. The Editors reserve the right to choose all reviewers and may not necessarily select reviewers from the list provided.
- Meeting Reports – based on the decision of the Editor.
- Special Articles – depending on the format and content, special articles may be solely based on the decision of the Editor, or undergo our standard review process.

Canada Post Publications Mail
Account Number: 40020215

Printed in Canada

ISSN (Print): 1198-0052
ISSN (Online): 1718-7729

CURRENT ONCOLOGY

A Canadian Cancer Research Journal

VOLUME 27, NUMBER 3, JUNE 2020

EDITORIAL

- 125 The challenge of creating evidence-based clinical practice guidelines for the use of hyperthermic intraperitoneal chemotherapy in the management of peritoneal malignancies**

G.C. Knapp BSc MSc MD and L.A. Mack BSc MSc MD

ORIGINAL ARTICLES

Knowledge Translation

- e246 Evaluation of a routine screening program with tuberculin skin testing on rates of detection of latent tuberculosis infection and prevention of active tuberculosis in patients with multiple myeloma at a Canadian cancer centre**

Full-text e-manuscript available at www.current-oncology.com

M. Gitman MD, J. Vu BSc, T. Nguyen RN MSN, C. Chen MD, and
C. Rotstein MD

Surgical Oncology

- e251 Real-world impact of laparoscopic surgery for rectal cancer: a population-based analysis**

Full-text e-manuscript available at www.current-oncology.com

A.E. Drohan MD, C.M. Hoogerboord MD, P.M. Johnson MD,
G.J. Flowerdew DSc, and G.A. Porter MD

- e259 Prognosis and clinicopathologic features in patients with gastric stump cancer after curative surgery**

Full-text e-manuscript available at www.current-oncology.com

C.Y. Kung MD, W.L. Fang MD PhD, R.F. Wang MD PhD, C.A. Liu MD,
A.F.Y. Li MD PhD, C.W. Wu MD, Y.M. Shyr MD, S.C. Chou MD, and
K.H. Huang MD PhD

Medical Oncology

- 127 Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors**

Full-text e-manuscript available at www.current-oncology.com

N.J. Lipton BA, J. Jesin BSc, E. Warner MD MSc, X. Cao PhD, A. Kiss PhD,
D. Desautels MD, and K.J. Jerzak MD MSc

e265 Does the time from diagnostic biopsy to neoadjuvant chemotherapy affect the rate of pathologic complete response in stages I-III breast cancer?

Full-text e-manuscript available at www.current-oncology.com

D. Le MD MHA, M. Eslami MD, H. Li MHA, O. Hajjaj, S. Chia MD, and C. Simmons MD MSc

e271 Access to cancer care in northwestern Ontario—a population-based study using administrative data

Full-text e-manuscript available at www.current-oncology.com

M. Febbraro MD, M. Conlon PhD, J. Caswell PhD, and
N. Laferriere MD PhD

e276 Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study

Full-text e-manuscript available at www.current-oncology.com

A. Deruchie Tan BSc, K. Willemsma BSc, A. MacNeill MD, K. DeVries MSc,
A. Srikanthan MD MSc, C. McGahan MSc, T. Hamilton MD, H. Li BSc, C.D. Blanke MD,
and C.E. Simmons MD MSc

Radiation Oncology

e283 Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer

Full-text e-manuscript available at www.current-oncology.com

J. Jin BM, Y. Xu MD, X. Hu MD, M. Chen MD, M. Fang MD, Q. Hang BM, and M. Chen MD

Cancer Control and Prevention

e294 Investigating epidemiologic trends and the geographic distribution of patients with anal squamous cell carcinoma throughout Canada

Full-text e-manuscript available at www.current-oncology.com

L. Cattelan BSc MD, F.M. Ghazawi MD PhD, M. Le BSc MD, E. Savin MD PhD, A. Zubarev MSc,
F. Lagacé BSc MD, D. Sasseville MD, K. Waschke MD, and I.V. Litvinov MD PhD

Biomarkers in Oncology

135 Inflammatory markers as prognostic factors of recurrence in advanced-stage squamous cell carcinoma of the head and neck

M. Valdes MD, J. Villeda MD, H. Mithoowani MD, T. Pitre MA MD, and
M. Chasen MBChB FCP(SA) MPhil (Pall Med)

Clinical Trials

e307 Barriers to conducting cancer trials in Canada: an analysis of key informant interviews

Full-text e-manuscript available at www.current-oncology.com

C. Bentley PhD, S. Sundquist, J. Dancey MD, and S. Peacock DPhil

SPECIAL ARTICLE

142 Management of dyspnea in palliative care

A.M. Crombeen MD CCFP(PC) and E.J. Lilly MD CCFP

PRACTICE GUIDELINES

146 Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline

R.C. Auer MD, D. Sivajohanathan MPH, J. Biagi MD, J. Conner MD, E. Kennedy MD, and T. May MD

e313 Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic

Full-text e-manuscript available at www.current-oncology.com

N. Blais MD MSc, M. Bouchard MD, M. Chinas, H. Lizotte MSc, M. Morneau MSc MBA, J. Spicer MD PhD, and S. Martel MD

e318 Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline

Full-text e-manuscript available at www.current-oncology.com

F.C. Wright MD MEd, S. Kellett MEnvSc, N.J. Look Hong MD MSc, A.Y. Sun MD, T.P. Hanna MD, C. Nessim MD MSc, C.A. Giacomantonio MD MSc, C.F. Temple-Oberle MD MSc, X. Song MD, and T.M. Petrella MD MHSc

e326 Consensus statement on tumour bed localization for radiation after oncoplastic breast surgery

Full-text e-manuscript available at www.current-oncology.com

T. Tse MD MSc, S. Knowles MD MSc, J. Bélec PhD, J.M. Caudrelier MD PhD, M. Lock MD, M. Brackstone MD PhD, and A. Arnaout MD MSc

SHORT COMMUNICATIONS

155 Tumour response 3 months after neoadjuvant single-fraction radiotherapy for low-risk breast cancer

Full-text e-manuscript available at www.current-oncology.com

D. Tiberi MD, P. Vavassis MD, D. Nguyen MD, M.C. Guilbert MD, A. Simon-Cloutier MD, P. Dubé MD, M.K. Gervais MD, L. Sideris MD, G. Leblanc MD, T. Hijal MD, M.P. Dufresne MD, and M. Yassa MD

e332 Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic

Full-text e-manuscript available at www.current-oncology.com

L.H. Sehn MD, P. Kuruvilla MD, A. Christofides MSc RD, and J. Stakiw MD

e336 Women's views about breast cancer prevention at mammography screening units and well women's clinics

Full-text e-manuscript available at www.current-oncology.com

A. Rundle BSc MD, S. Iles MD, K. Matheson MSc, L.E. Cahill PhD RD, C.C. Forbes PhD, N. Saint-Jacques MSc PhD, R. Urquhart PhD, and T. Younis MBBCh

e343 Validation in Alberta of an administrative data algorithm to identify cancer recurrence

Full-text e-manuscript available at www.current-oncology.com

Z.F. Cairncross MPH, G. Nelson MD PhD, L. Shack PhD, and A. Metcalfe PhD

COMMENTARIES

159 Impact of the COVID-19 outbreak on adjuvant chemotherapy for patients with stage II or III colon cancer: experiences from a multicentre clinical trial in China

L. Sun MD, Y. Xu MD, T. Zhang MD, and Y. Yang MD

163 Preparing for the renaissance: treating breast cancer during the COVID-19 pandemic and planning for a safe re-emergence to routine surgical care within a universal health care system

Full-text e-manuscript available at www.current-oncology.com

D. Berger-Richardson MD MSc, G. Ko MD, and N.J. Look Hong MD MSc

CASE REPORT

169 PD-1 inhibition in malignant melanoma and lack of clinical response in chronic lymphocytic leukemia in the same patients: a case series

I. Landego MD, D. Hewitt RN, I. Hibbert BN, D. Dhaliwal MD, W. Pieterse MD, D. Grenier BSc MD, R. Wong BSc MD, J. Johnston MB BCh, and V. Banerji MD

CANCER NARRATIVE

e347 At a loss

Full-text e-manuscript available at www.current-oncology.com

D. Schep MD MSc

LETTER TO THE EDITOR

e348 Re: Renal medullary carcinoma and its association with sickle cell trait: a case report and literature review

Full-text e-manuscript available at www.current-oncology.com

M. Riminucci MD PhD and A. Corsi MD PhD

ERRATUM

e349 Erratum: Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

Full-text e-manuscript available at www.current-oncology.com

A. Elkrief MD, P. Joubert MD, M. Florescu MD, M. Tehfe MD MSc, N. Blais MD MSc, and B. Routy MD PhD



Pr **Trisenox**[®]
(arsenic trioxide)
for Injection



NOW AVAILABLE
in new single-dose
12 mg/6 mL vials¹

Reference: 1. Trisenox[®] Product Monograph.
Teva Canada Limited. June 7, 2019.

TRISENOX is a registered trademark of Cephalon, Inc., an affiliate of
Teva Canada Innovation G.P. – S.E.N.C. and is used under licence.
© 2019 Teva Canada Innovation G.P. – S.E.N.C.
Montreal, Quebec, H2Z 1S8 TSX19-ADH01E



teva | Canada
Brands. Generics. Biosimilars.